ΨΥΧΗΣ ΙΑΤΡΕΙΟΝ
Dipeptidyl Peptidase 4 Inhibitors
Alogliptin (trade name Nesina in the US and Vipidia in Europe) is an orally administered anti-diabetic drug in the DPP-4 inhibitor class. Like other medications for the treatment of Type 2 diabetes, alogliptin does not decrease the risk of heart attack and stroke... Wikipedia
Manufacturer's Website: Nesina Average retail cost: $520/30 tabs
Nesina (alogliptin)
* Prices reflect U.S. average retail price
Linagliptin (INN, previously known as BI-1356, marketed under trade names Tradjenta (U.S.) and Trajenta (worldwide)) is a dipeptidyl peptidase-4 inhibitor developed by Boehringer Ingelheim for treatment of diabetes mellitus type 2... Wikipedia
Manufacturer's Website: Tradjenta Average retail cost: $511/30 tabs
Tradjenta (linagliptin)
Sitagliptin (INN; marketed as the phosphate salt under the trade name Januvia) is an oral antihyperglycemic (antidiabetic drug) of the dipeptidyl peptidase-4 (DPP-4) inhibitor class. It was developed, and is marketed, by Merck & Co. This enzyme-inhibiting drug is used either alone or in combination with other oral antihyperglycemic agents (such as metformin or a thiazolidinedione) for treatment of diabetes mellitus type 2... Wikipedia
Manufacturer's Website: Januvia Average retail cost: $729/30 tabs
Januvia (sitagliptin)
Discontinued by manufacturer